The European Medicines Agency endorses a booster dose of Pfizer targeting two strains of Omicron
Today, Monday, the European Medicines Agency recommended a booster dose against the emerging coronavirus (Covid-19) designed to combat the Omicron sub-strains PA4 and PA5, days after the approval of two booster doses designed to combat the older strain PA1. .
The latest approval relates to a so-called bivalent vaccine developed by Pfizer and Biotech that targets the PA4 and PA5 sub-strains, as well as the Omicron strain of the coronavirus that originally appeared in China in December 2019.
The European Medicines Agency's recommendation includes authorizing the vaccination of those aged 12 and over who have received at least the basic vaccination against Covid-19.
Final approval of the dose is subject to European Commission approval, which is expected to come soon.
Pfizer said in a statement on Monday that if the booster PA5/4 is allowed, it will be available within days to all 27 member states of the European Union.
Earlier this month, the European Medicines Agency approved two updated Pfizer/Biontech and Moderna vaccines to combat PA1.
Follow our latest local and sports news and the latest political and economic developments via Google news